Navellier & Associates Inc. Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Navellier & Associates Inc. acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 178,745 shares of the biotechnology company’s stock, valued at approximately $3,065,000. Navellier & Associates Inc. owned about 0.08% of ADMA Biologics at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ADMA. Creative Planning increased its stake in ADMA Biologics by 52.0% in the third quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock valued at $1,098,000 after acquiring an additional 18,800 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in ADMA Biologics by 8.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 228,367 shares of the biotechnology company’s stock valued at $4,565,000 after acquiring an additional 17,573 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares during the last quarter. Highland Capital Management LLC bought a new position in ADMA Biologics in the third quarter valued at approximately $227,000. Finally, Louisiana State Employees Retirement System bought a new position in ADMA Biologics in the third quarter valued at approximately $2,253,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ADMA. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $15.84 on Friday. ADMA Biologics, Inc. has a fifty-two week low of $5.08 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. The company’s 50 day moving average price is $17.03 and its two-hundred day moving average price is $17.88.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.